Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, Nakanishi, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500214/
https://www.ncbi.nlm.nih.gov/pubmed/22849580
http://dx.doi.org/10.1186/1471-2407-12-327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500214/
https://www.ncbi.nlm.nih.gov/pubmed/22849580
http://dx.doi.org/10.1186/1471-2407-12-327

Ejemplares similares